Eli Lilly Alzheimer’s treatment solanezumab failed to slow disease progression
Solanezumab's failure is a blow to efforts to treat Alzheimer's in people who have not yet shown clinical symptoms.
Source link
- China’s Shein set to raise $2 billion in new funding round, aims for U.S. IPO later this year, sources say
- Russia-Ukraine war: List of key events, day 379
